- Home
- TARA vs PALI Comparison
TARA vs PALI Comparison
Compare TARA & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARA | PALI |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.5M | 240.2M |
| IPO Year | 2014 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TARA | PALI |
|---|---|---|
| Price | $5.11 | $1.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $21.67 | $12.00 |
| AVG Volume (30 Days) | 673.0K | ★ 3.9M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.25 | ★ 97.06 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,948,000.00 | $260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $2.77 | $0.55 |
| 52 Week High | $7.82 | $2.64 |
Technical Indicators
Market Signals| Indicator | TARA | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 42.79 | 50.99 |
| Support Level | $4.95 | $1.58 |
| Resistance Level | $5.39 | $2.05 |
| Average True Range (ATR) | 0.29 | 0.17 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 44.93 | 60.29 |
Price Performance
Historical ComparisonAbout TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.